Matrix-M1 adjuvant
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- Matrix-M1 adjuvant
- matrix m
- Matrix M
- matrix m1 adjuvant
- Matrix-m
- Matrix-M
- Matrix-m1 adjuvant
- Matrix-M1 Adjuvant
- Matrix-M1™ adjuvant
- Matrix-M™
- ChEMBL ID
- CHEMBL4650407
- FDA ingredient codes (UNII)
- YZ7P8Y8ECX
- First in class
- No
- Orphan designation
- No
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Hemorrhagic Fever, Ebola
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007243
- Subject identifier
- D019142
- Condition
- Influenza, Human
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007243
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007328
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007444
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT02370589
- NCT02925403
- NCT03970993
- NCT04704830
- NCT05155579
- NCT05913973
- NCT03026348
- NCT03658629
- NCT03896724
- NCT03947190
- NCT04271306
- NCT04318002
- NCT05135273
- NCT05252845
- NCT05357560
- NCT04368988
- NCT04533399
- NCT04611802
- NCT04961541
- NCT05372588
- NCT05468736
- NCT05875701
- NCT06291857
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (41)
- A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
- A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
- A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
- A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
- A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
- A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
- A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants
- A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
- A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
- A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV
- Dose Finding Trial of R21/Matrix-M in School Children
- Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
In development for (7)
- COVID-19 Phase 3
- Ebola hemorrhagic fever Phase 1
- Influenza Phase 2
- Malaria Phase 3
- Plasmodium falciparum malaria Phase 2
- Respiratory syncytial virus infectious disease Phase 2
- Severe acute respiratory syndrome Phase 3